vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $246.6M, roughly 1.2× Claritev Corp). Bio-Techne runs the higher net margin — 12.8% vs -32.7%, a 45.5% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 2.5%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CTEV vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $295.9M |
| Net Profit | $-80.6M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3.1% | 18.4% |
| Net Margin | -32.7% | 12.8% |
| Revenue YoY | 6.2% | -6.4% |
| Net Profit YoY | 41.6% | 68.3% |
| EPS (diluted) | $-4.88 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $295.9M | ||
| Q3 25 | $246.0M | — | ||
| Q2 25 | $241.6M | $317.0M | ||
| Q1 25 | $231.3M | $316.2M | ||
| Q4 24 | $232.1M | $297.0M | ||
| Q3 24 | $230.5M | $289.5M | ||
| Q2 24 | $233.5M | $306.1M | ||
| Q1 24 | $234.5M | $303.4M |
| Q4 25 | $-80.6M | $38.0M | ||
| Q3 25 | $-69.8M | — | ||
| Q2 25 | $-62.6M | $-17.7M | ||
| Q1 25 | $-71.3M | $22.6M | ||
| Q4 24 | $-138.0M | $34.9M | ||
| Q3 24 | $-391.4M | $33.6M | ||
| Q2 24 | $-576.7M | $40.6M | ||
| Q1 24 | $-539.7M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -3.1% | 18.4% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 6.9% | -7.5% | ||
| Q1 25 | 4.2% | 12.2% | ||
| Q4 24 | -17.8% | 16.0% | ||
| Q3 24 | -146.7% | 13.8% | ||
| Q2 24 | -224.4% | 15.0% | ||
| Q1 24 | -207.4% | 22.1% |
| Q4 25 | -32.7% | 12.8% | ||
| Q3 25 | -28.4% | — | ||
| Q2 25 | -25.9% | -5.6% | ||
| Q1 25 | -30.8% | 7.1% | ||
| Q4 24 | -59.4% | 11.7% | ||
| Q3 24 | -169.8% | 11.6% | ||
| Q2 24 | -247.0% | 13.3% | ||
| Q1 24 | -230.1% | 16.2% |
| Q4 25 | $-4.88 | $0.24 | ||
| Q3 25 | $-4.23 | — | ||
| Q2 25 | $-3.81 | $-0.11 | ||
| Q1 25 | $-4.38 | $0.14 | ||
| Q4 24 | $-8.49 | $0.22 | ||
| Q3 24 | $-24.25 | $0.21 | ||
| Q2 24 | $-35.78 | $0.26 | ||
| Q1 24 | $-33.40 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $172.9M |
| Total DebtLower is stronger | $4.6B | $260.0M |
| Stockholders' EquityBook value | $-173.9M | $2.0B |
| Total Assets | $4.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $172.9M | ||
| Q3 25 | $39.2M | — | ||
| Q2 25 | $56.4M | $162.2M | ||
| Q1 25 | $23.1M | $140.7M | ||
| Q4 24 | $16.8M | $177.5M | ||
| Q3 24 | $86.6M | $187.5M | ||
| Q2 24 | $48.8M | $152.9M | ||
| Q1 24 | $58.7M | $145.3M |
| Q4 25 | $4.6B | $260.0M | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | $346.0M | ||
| Q1 25 | $4.5B | $330.0M | ||
| Q4 24 | $4.5B | $300.0M | ||
| Q3 24 | $4.5B | $300.0M | ||
| Q2 24 | $4.5B | $319.0M | ||
| Q1 24 | $4.5B | $389.0M |
| Q4 25 | $-173.9M | $2.0B | ||
| Q3 25 | $-101.8M | — | ||
| Q2 25 | $-39.9M | $1.9B | ||
| Q1 25 | $14.8M | $2.0B | ||
| Q4 24 | $84.0M | $2.1B | ||
| Q3 24 | $207.6M | $2.1B | ||
| Q2 24 | $603.4M | $2.1B | ||
| Q1 24 | $1.2B | $2.0B |
| Q4 25 | $4.9B | $2.5B | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.1B | $2.6B | ||
| Q1 25 | $5.1B | $2.6B | ||
| Q4 24 | $5.2B | $2.7B | ||
| Q3 24 | $5.3B | $2.7B | ||
| Q2 24 | $5.7B | $2.7B | ||
| Q1 24 | $6.4B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | 304.87× | 0.16× | ||
| Q4 24 | 53.67× | 0.14× | ||
| Q3 24 | 21.73× | 0.14× | ||
| Q2 24 | 7.48× | 0.15× | ||
| Q1 24 | 3.85× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | — |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | — | ||
| Q3 25 | $19.9M | — | ||
| Q2 25 | $61.2M | $98.2M | ||
| Q1 25 | $-30.1M | $41.1M | ||
| Q4 24 | $-33.4M | $84.3M | ||
| Q3 24 | $72.8M | $63.9M | ||
| Q2 24 | $18.5M | $75.5M | ||
| Q1 24 | $49.7M | $81.0M |
| Q4 25 | $36.4M | — | ||
| Q3 25 | $-16.3M | — | ||
| Q2 25 | $36.6M | $93.3M | ||
| Q1 25 | $-68.9M | $31.0M | ||
| Q4 24 | $-63.8M | $77.5M | ||
| Q3 24 | $41.1M | $54.7M | ||
| Q2 24 | $-7.0M | $57.5M | ||
| Q1 24 | $19.2M | $64.5M |
| Q4 25 | 14.8% | — | ||
| Q3 25 | -6.6% | — | ||
| Q2 25 | 15.2% | 29.4% | ||
| Q1 25 | -29.8% | 9.8% | ||
| Q4 24 | -27.5% | 26.1% | ||
| Q3 24 | 17.8% | 18.9% | ||
| Q2 24 | -3.0% | 18.8% | ||
| Q1 24 | 8.2% | 21.3% |
| Q4 25 | 12.1% | — | ||
| Q3 25 | 14.7% | — | ||
| Q2 25 | 10.2% | 1.5% | ||
| Q1 25 | 16.8% | 3.2% | ||
| Q4 24 | 13.1% | 2.3% | ||
| Q3 24 | 13.8% | 3.2% | ||
| Q2 24 | 10.9% | 5.9% | ||
| Q1 24 | 13.0% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
